JNCCN 360 - B-Cell Lymphomas - Ongoing CE Activities

Editor:

Leo I. Gordon, MD, FACP

Advertisement

Advertisement

Ongoing CE Activities

BTK Inhibitors for CLL and MCL: A Settling Storm or Just the Beginning?

Challenging Cases from the Community: Investigators Provide Perspectives on the Optimal Management of Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma: Evolution of Treatment Approaches

Exploring the Current and Changing Paradigm for the Management of Newly Diagnosed Diffuse Large B‑Cell Lymphoma

Follicular Lymphoma Updates for the Oncology Care Team: Data and Clinical Insights

Mantle Cell Lymphoma: Exploring the Feasibility of Moving BTK Inhibitors to the Frontline

Meet The Professor: Optimizing the Clinical Management of Hodgkin and Non-Hodgkin Lymphomas — Part 7 of an 8-Part Series

Oncology Today with Dr Neil Love: Current and Future Management of Hodgkin Lymphoma

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

Updates for the Community Provider From New Orleans: BTK Inhibitors in B-Cell Malignancies

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Hodgkin and Non-Hodgkin Lymphoma

What I Tell My Patients: Expert Insights into Patient Education on New Treatments and Clinical Trial Participation in Hodgkin and Non-Hodgkin Lymphomas

Clinical Investigator Perspectives on New Data Sets and Advances in Follicular Lymphoma

Sections

NCCN Resources

Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.